Core Viewpoint - Altimmune's experimental drug has shown positive results in improving liver scarring and overall liver health after 48 weeks of treatment in a mid-stage study focused on patients with serious fatty liver disease [1] Group 1 - The drug demonstrated significant improvement in liver health indicators after a 48-week treatment period [1] - The study involved patients suffering from a serious condition known as fatty liver disease [1]

Core Insights - Altimmune, Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks [2][3] Group 1: Trial Results - Statistically significant improvements in key non-invasive markers of fibrosis, including Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), were observed across treatment arms compared to placebo [3][5] - The 1.2 mg and 1.8 mg doses of pemvidutide achieved mean reductions in ELF of -0.49 and -0.58 respectively, versus +0.16 in placebo (p<0.0001) [5] - The 1.2 mg and 1.8 mg doses achieved mean reductions in LSM of -3.04 (p<0.05) and -3.97 (p<0.001) respectively, compared to -0.03 in placebo [5] - Participants receiving pemvidutide also showed significant reductions in liver fat content, alanine aminotransferase (ALT), and corrected T1 (cT1) [5] - Weight loss was observed with the 1.2 mg and 1.8 mg doses at 4.5% and 7.5% respectively, compared to 0.2% in placebo (p<0.0001) [13] Group 2: Tolerability and Safety - The tolerability profile of pemvidutide was favorable at 48 weeks, with low treatment-related discontinuation rates of 0% and 1.2% for the 1.2 mg and 1.8 mg doses respectively, compared to 3.5% for placebo [13] - No serious or severe adverse events related to treatment were reported [13] Group 3: Regulatory Progress - The company held a productive End-of-Phase 2 meeting with the FDA, aligning on parameters for a registrational Phase 3 trial for pemvidutide in MASH patients with moderate to advanced liver fibrosis [6][7] - The FDA's qualification of AIM-MASH AI Assist was noted, which aims to standardize histologic assessment in the Phase 3 trial [6] Group 4: Future Plans - The company plans to initiate the Phase 3 program for pemvidutide in 2026, leveraging the strong evidence of antifibrotic improvements and favorable tolerability [7]

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigma Corporation, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - ALT5 Sigma provides blockchain-powered technologies through its Fintech and Biotechnology segments [2] - On August 11, 2025, ALT5 Sigma announced plans to raise approximately $1.5 billion before fees through a registered direct offering and a private placement offering [2] Recent Developments - On August 29, 2025, ALT5 Sigma disclosed a judgment from the Intermediate Court of Nyarugenge, Rwanda, finding its subsidiary criminally liable for offenses including illicit enrichment and money laundering [3] - An independent committee was appointed by the Board to investigate potential misstatements or omissions in the financial statements [3] - On October 22, 2025, Peter Tassiopoulos was suspended as CEO, effective immediately, with pay [3] - ALT5 Sigma announced on November 18, 2025, that it would not file its Quarterly Report on Form 10-Q for that quarter in a timely manner [3] - A leadership overhaul occurred on November 27, 2025, with the rapid departures of the CFO, Acting CEO, and COO, alongside the appointment of a new Acting CEO and an experienced CFO [3] - On November 28, 2025, ALT5 Sigma's independent registered public accounting firm resigned due to the retirement of its sole partner [3] - On December 3, 2025, ALT5 Sigma received a notice from Nasdaq regarding non-compliance with listing requirements due to the resignation of a Board member [3]

Core Viewpoint - Altimmune, Inc. (ALT) has shown a significant price increase of 28.4% over the past four weeks, with a mean price target of $17.88 indicating a potential upside of 229.3% from the current price of $5.43 [1] Price Targets and Analyst Consensus - The average price target for ALT includes eight short-term estimates ranging from a low of $1.00 to a high of $28.00, with a standard deviation of $8.81, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 81.6%, while the highest points to an upside of 415.7% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction, which can be a useful starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ALT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.8%, with one estimate moving higher and no negative revisions [12] - ALT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and consider them as one of many factors in their decision-making process [10]

Core Insights - ALT5 Sigma Corporation has released a strategic overview regarding the USD1 stablecoin and its significance to the company's long-term payments technology product [1] - The company is a prominent holder of $WLFI, which is the governance token of the World Lib [1] Company Overview - ALT5 Sigma Corporation operates in the fintech sector, focusing on global payments, trading, and settlement infrastructure [1] - The anticipated benefits of the USD1 stablecoin are expected to enhance the company's $WLFI Treasury Strategy [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against ALT5 Sigma Corp for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether ALT5 has engaged in unlawful activities that may have led to financial losses for investors [1][2]. - Investors who have suffered losses and wish to discuss their legal rights are encouraged to contact the law firm [3]. Company Developments - On August 29, 2025, ALT5 disclosed that its subsidiary was found criminally liable for illicit enrichment and money laundering, leading to a significant drop in share price by approximately 29.2% [6]. - Following the suspension of CEO Peter Tassiopoulos on October 22, 2025, the share price fell by about 8.8% [6]. - ALT5 announced delays in filing its quarterly report due to ongoing reviews and issues with its outside auditor [6]. - The company terminated CFO and acting CEO Jonathan Hugh on November 26, 2025, and the Audit Committee Chair resigned from the board [6]. - On November 28, 2025, ALT5's outside auditor resigned on the same day as the CFO's termination [6].

Core Viewpoint - ALT5 Sigma Corporation is advancing its strategic $WLFI digital asset treasury initiative, focusing on innovation and agility to drive growth across its business segments [2][3]. Group 1: $WLFI Treasury Strategy - ALT5 launched the $WLFI Treasury strategy to gain structured exposure to the $WLFI ecosystem and optimize the number of $WLFI tokens held per share through strategic capital deployment [3]. - The treasury strategy aims to strengthen ALT5's balance sheet and enhance long-term capital flexibility, creating synergies across payments, trading, settlement, and digital asset treasury operations [3]. - As of December 8, 2025, ALT5 holds approximately 7.28 billion $WLFI tokens, valued at around $1.1 billion, with a market price of $0.15 per token [6]. Group 2: Fintech & Payments Business - ALT5's Fintech & Payments business includes ALT5 Pay and ALT5 Prime, which have processed over $5 billion in cryptocurrency transactions, highlighting their scale and reliability [7]. - ALT5 Pay facilitates secure digital asset transactions and supports crypto-to-fiat and fiat-to-crypto conversions, enabling real-time global payment flows [8]. - ALT5 Prime provides traditional financial institutions with access to digital asset trading and real-time settlement, generating revenue from spread capture and transaction fees [9][10]. Group 3: Biotech Business - ALT5's legacy biotech business, Alyea Therapeutics Corporation, is focused on advancing clinical trials for non-addictive pain treatment patents, aiming to increase the business's realizable value [12]. Group 4: Future Outlook - ALT5 believes that the advancements in its $WLFI Treasury strategy and the integration of $USD1 across its platforms position the company for sustained innovation and growth in digital finance solutions [13].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?In my last note on Altimmune, Inc. ( ALT ) back in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, andEdmund Ingham ...

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Industry**: Biotechnology, specifically focusing on liver diseases and metabolic disorders Key Points and Arguments Leadership Transition - Transition from Vipin to Jerry as CEO is seen as timely and strategic for Altimmune's next phase, particularly as the company approaches a large Phase 3 program [4][5][6] - Jerry's experience with Intercept and the launch of Ocaliva is expected to bring valuable commercial expertise to Altimmune [4][5] Pemvidutide Development - Pemvidutide is highlighted as a key product with potential benefits for liver disease, weight loss, and metabolic parameters [5][6] - The company is preparing for an end-of-phase two meeting with the FDA, which is scheduled and will be in-person [9][10] - Upcoming 48-week data is anticipated to provide insights into the drug's efficacy and safety [9][27] Regulatory Strategy - The company aims to align with the FDA on flexible Phase 3 design, potentially incorporating AI-based reading or non-invasive tests (NITs) as endpoints [10][12] - The use of AI is expected to reduce bias in assessments and improve the accuracy of data [13][26] Clinical Data Insights - At 24 weeks, significant results were observed, including MASH resolution without worsening fibrosis, defatting of the liver, and weight loss while preserving lean muscle mass [31][32] - The company aims to maintain or improve these results at the 48-week mark, focusing on tolerability and continued weight loss [33][34] Alcohol Use Disorder (AUD) and Alcoholic Liver Disease (ALD) - Altimmune is pursuing indications for AUD and ALD, leveraging the unique benefits of pemvidutide [42][44] - The primary endpoint for the AUD study is the reduction in heavy drinking days, with additional biomarkers being tracked [48] Market Strategy and Commercialization - Jerry emphasizes the importance of being externally focused and understanding market dynamics as the company transitions from a developmental to a commercial entity [51][52] - The strategic focus is on building and enhancing the pemvidutide program, with plans to differentiate it in the market [58] Future Outlook - The company is optimistic about the upcoming data readouts and the potential for pemvidutide to address significant unmet needs in liver diseases [46][49] - The leadership transition is expected to enhance Altimmune's capabilities and strategic direction moving forward [56][58] Additional Important Insights - The company is focused on ensuring patient retention on chronic therapies, which is critical for long-term success [32][34] - The combination of glucagon and GLP-1 in pemvidutide is seen as a promising approach for treating both MASH and AUD/ALD [42][47] - The enrollment for the AUD trial was completed ahead of schedule, indicating strong interest and potential in this indication [45]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...